Advertisement

Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind Multicenter Study, Austria

  • G. F. Hebenstreit
  • M. Loidl
  • U. Baumhackl
  • B. Gallhofer
  • Ch. Geretsegger
  • E. Radmayr
  • M. Saletu
  • W. Schöny
  • M. Stabl
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)

Summary

In a double-blind, 4-week, prospective, randomized multicenter (17 centers) study we checked on the efficacy, tolerability and safety of moclobemide (300–600 mg/d) compared to imipramine (100–200 mg/d) in parallel groups of patients with a Major Depressive Episode (DSM III).

The mean % reduction of the HAMD at the end of treatment was 51.7 in the moclobemide group and 52.1 in the imipramine group. The percentage of patients in whom efficacy was globally judged as “good” or “very good” was 62% in the moclobemide group and 60% in the imipramine group.

Keywords

Major Depressive Disorder Major Depressive Episode Hamilton Depression Rate Scale Anticholinergic Adverse Event Generation MAOIs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Angst J (1986) Allgemeine Aspekte zur Behandlung mit Antidepressiva. In: Schmid-Burgk W Koella W (Hrsg) Neue Aspekte der Therapie mit Antidepressiva. Fischer, Stuttgart New York.Google Scholar
  2. Baumhackl U, Biziere K Fischbach R, Geretsegger Ch, Hebenstreit G, Radmayr E, Stabl M (1990) Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM III): an Austrian double-blind, multicentre study. Br J Psychiatry 155 [Suppl] 6:78–83.Google Scholar
  3. Davidson J, McCleod MN, Blum MR (1978) Acetylation phenotype, platelet monoamine oxidase inhibitor and the effectiveness of phenelzine in depression. Am J Psychiatry 135:467–469.PubMedGoogle Scholar
  4. Hebenstreit GF (1988) Efficacy and safety of moclobemide compared to imipramine in patients with major depression: results of an Austrian multicenter double-blind trial. Neurologija 37 [Suppl] 1:25.Google Scholar
  5. Hebenstreit GF, et al. (1990) Efficacy, safety and tolerability of moclobemide compared with imipramine in the treatment of major depressive disorder. WPA-Regional Symposium, book of abstracts, p 114.Google Scholar
  6. Kline NS, Cooper TB (1980) Monoamine oxidase inhibitors as antidepressants. In: Hoffmeister F, Stille G (eds) Psychotropic agents, part I. Antipsychotics and antidepressants. Springer, Berlin Heidelberg New York, pp 369–397.Google Scholar
  7. Paykel ES (1971) Classification of depressed patients: a cluster analysis derived grouping. Br J Psychiatry 188:275–288.CrossRefGoogle Scholar
  8. Robinson DS, Nies A, Ravaris CL, Ives JO, Bertlett D (1978) Clinical psycho-pharmacology of phenelzine: MAO activity and clinical response. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York.Google Scholar
  9. West ED, Dally LJ (1959) Effects of iproniazid in depressive syndromes. Br Med J 1:1491–1494.PubMedCrossRefGoogle Scholar
  10. WHO Collaborative Study (1986) J Affect Dis 2:1–67.Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • G. F. Hebenstreit
    • 1
  • M. Loidl
    • 2
  • U. Baumhackl
    • 3
  • B. Gallhofer
    • 4
  • Ch. Geretsegger
    • 5
  • E. Radmayr
    • 6
  • M. Saletu
    • 7
  • W. Schöny
    • 8
  • M. Stabl
    • 9
  1. 1.NÖ LandesnervenklinikMauer/AmstettenAustria
  2. 2.Hoffmann-La Roche Wien, Ges. m.b.H.Austria
  3. 3.A.Ö. KrankenhausSt. PöltenAustria
  4. 4.Psychiatrisch Neurologische UniversitätsklinikGrazAustria
  5. 5.Landes-NervenklinikSalzburgAustria
  6. 6.Facharzt für Psychiatrie und NeurologieDornbirnAustria
  7. 7.Anton-Proksch-InstitutWien-KalksburgAustria
  8. 8.Wagner-Jauregg-Krankenhaus des Landes OberösterreichLinzAustria
  9. 9.F. Hoffmann-La Roche AGBaselSwitzerland

Personalised recommendations